OPOCX Mutual Fund

OPOCX Mutual Fund

NAV$102.52
See how much of OPOCX you already own
Just $25 once·$99/mo·Download sample
X-ray my portfolio free

Fund Essentials - as of Sep 30, 2026

Net Assets
$1.7B
Expense Ratio
1.03%
Dividend Yield (Current)
-
Holdings
97
Inception Date
Sep 11, 1986
Fund Family
Invesco (US)
Investment Style
PRO
Asset Class
PRO
Legal Structure
PRO
Dividend Frequency
Annually

Performance

YTD+11.87%
1 Year+12.74%
3 Year+23.94%
5 Year+4.16%
10 Year+14.76%

Asset Allocation

Stocks: 96.31%
Cash: 1.52%
Other: 2.18%
See how much of OPOCX you already own
Your funds unpacked, overlap, fees and score, free on screen. The full report comes with FundXLS. Download sample.
X-ray my portfolio free

Top Holdings

View All →
TickerNameWeight
LGNDLigand Pharmaceuticals Inc2.91%
FROGJFrog Ltd2.47%
RGENRepligen Corp2.35%
BTSGBrightSpring Health Services Inc2.18%
HALOHalozyme Therapeutics Inc2.08%
Top 10 Concentration: 21.55%Report Date: Sep 30, 2026
Download all 97 holdings for OPOCX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Frequency
Annually
Latest Distribution
$21.35
-

Peer Comparison

Benchmark
PRO
Peer outperformance: PRO
Category rank: PRO
This Mutual Fund
PRO
Peer Avg
PRO

OPOCX Mutual Fund Overview

OPOCX Mutual Fund (Invesco Discovery Fund Class A) is managed by Invesco (US) with $1.72B in net assets. OPOCX expense ratio is 1.03%, holding 97 positions across sectors including Health Care, Information Technology, Industrials. Inception date: 1986-09-11.

OPOCX performance shows a YTD return of 11.87%. The 1-year return is 12.74% and the 5-year return is 4.16%.

OPOCX top holdings include Ligand Pharmaceuticals Inc (2.9%), JFrog Ltd (2.5%), Repligen Corp (2.4%), BrightSpring Health Services Inc (2.2%), Halozyme Therapeutics Inc (2.1%). Go to all OPOCX holdings, OPOCX sectors, or OPOCX dividends.

OPOCX can be compared against other funds. Use OPOCX overlap to find shared positions, or OPOCX vs another fund for a side-by-side view. OPOCX alternatives are available via the screener, along with tax-loss harvesting opportunities.